At CellMark360, we’re pioneering regenerative medicine by harnessing the power of your own cells to support healing in conditions like knee arthritis. Our advanced technology isolates autologous stromal vascular fraction (SVF) from adipose (fat) tissue, offering a safe, natural, and effective solution to promote regeneration and restoration. Below, we present a comprehensive review of peer-reviewed studies on human participants, spotlighting a landmark study using CellMark360 technology, to demonstrate the potential of SVF for supporting knee arthritis recovery. This report is designed for both doctors and prospective patients, highlighting the transformative impact of SVF.

Knee osteoarthritis occurs when cartilage in your knee joint wears down, causing discomfort and limiting movement. Unlike conventional methods like painkillers or surgery, which may only mask symptoms or carry risks, CellMark360’s SVF therapy uses your own cells to encourage healing and regeneration [5, 7, 9, 10]. Adipose tissue is a rich source of stem cells—containing 500 to 2000 times more stem cells than bone marrow—and can be harvested less invasively [19, 21]. SVF contains a variety of cells, including mesenchymal stem cells, which can reduce inflammation, modulate immune responses, and potentially support cartilage regeneration [8, 12, 19].

The studies reviewed here involve human participants with knee osteoarthritis who received autologous SVF. A landmark study by Berman et al. (2019) included 2,586 patients, using standardized protocols later adopted in CellMark360 technology, with follow-ups extending up to 5 years [Berman et al., 2019]. Other studies, such as those by Michalek et al. (2017) and Pak (2011), also provide insights, with follow-ups ranging from months to years [1, 3]. Researchers used tools like the Visual Analog Scale (VAS) for pain and assessed functional improvement through patient-reported outcomes, alongside imaging like X-rays to evaluate structural changes [1, 3, Berman et al., 2019].

The landmark study by Berman et al. (2019), utilizing protocols integral to CellMark360 technology, demonstrated SVF’s effectiveness in supporting recovery across 2,586 patients. At 1 year, 80.49% of 615 patients reported improvement in pain or function, a trend that held steady with 77.83% of 212 patients at 2 years. Patients with severe walking pain (baseline 7-10 on VAS) saw pain drop from 7.31 to 3.05 (left knee) and 7.39 to 3.31 (right knee) after 1 year (p<0.0001). Those with moderate pain (baseline 1-6) reported reductions from 4.29 to 2.11 (left knee) and 4.32 to 2.26 (right knee) (p<0.0001). Even at 5 years, all 4 remaining respondents reported sustained benefits [Berman et al., 2019]. For patients, this means less discomfort and better mobility, enabling activities like walking, golfing, or even competitive sports.

Supporting these findings, Michalek et al. (2017) followed 1,128 patients with osteoarthritis, including knee cases, for up to 54 months. They found that 63% of patients experienced at least a 75% improvement in pain and function, with 91% seeing at least a 50% improvement, as measured by modified KOOS scores [1]. Pak (2011) reported a case where a patient with knee osteoarthritis, after receiving SVF with platelet-rich plasma (PRP), showed pain reduction and improved range of motion within 3 months, sustained at 12 months [3]. These studies collectively highlight SVF’s potential to support lasting recovery.

Beyond symptom relief, SVF may support structural restoration. In the Berman et al. (2019) study, X-rays of some patients showed increased joint space post-SVF deployment, suggesting possible cartilage regeneration [Berman et al., 2019]. Similarly, Pak (2011) noted MRI evidence of cartilage-like tissue regeneration in a knee osteoarthritis patient at 3 and 12 months post-SVF [3]. These findings indicate that CellMark360’s approach may help restore joint health over time, offering hope for long-term recovery [12].

The Berman et al. (2019) study found that outcomes varied with patient factors. Patients with a normal BMI (18.5-25) experienced greater pain reduction (from 4.54 to 2.55 for the left knee at 1 year) compared to those with a BMI over 30 (from 5.50 to 3.09) (p<0.0001 for both). However, all groups showed improvement, demonstrating SVF’s broad applicability [Berman et al., 2019]. Michalek et al. (2017) also noted that patients with higher BMI or more advanced OA had slower improvements, suggesting earlier intervention may optimize outcomes [1]. There was no significant difference in results between men and women or across age groups, and adding PRP to SVF did not enhance outcomes significantly [Berman et al., 2019].

Safety is a cornerstone of CellMark360’s approach, and the research confirms SVF’s safety profile. The Berman et al. (2019) study reported no serious adverse events (e.g., death, hospitalization, infections, or emboli) among 2,586 patients. Minor issues included temporary knee swelling (0.28% of cases), which resolved with steroid injections, and liposuction site discomfort (1.1%) [Berman et al., 2019]. No increased cancer risk was observed, with incidences matching general population rates [2, 20]. Michalek et al. (2017) also reported no serious side effects over 54 months [1]. This low-risk profile makes SVF a safer alternative to invasive options like surgery [11, 15, 16, 17, 18].

The evidence, particularly from the landmark Berman et al. (2019) study using CellMark360 technology, shows that autologous SVF can significantly reduce pain, improve mobility, and potentially support cartilage regeneration in knees affected by arthritis [Berman et al., 2019]. With an excellent safety profile and broad applicability across patient groups, SVF offers a natural alternative for those seeking to avoid surgery [1, 3, 20]. For doctors, CellMark360 provides a turnkey solution backed by decades of expertise, clinical data, and a supportive network of regenerative medicine professionals [4, 6, 8].

Ready to experience the CellMark360 difference? Join us in shaping the future of regenerative medicine, where your own cells hold the key to healing.For more information or to get started, visit www.CellMark360.com or contact us at support@cellmark360.com

• [1] Michalek J, et al. Stromal vascular fraction cells of adipose and connective tissue in people with osteoarthritis: A case control prospective multi-centric non-randomized study. Global Surgery. 2017;3:1-9.
• [2] Centeno CJ, et al. A multi-center analysis of adverse events among two thousand, three hundred and seventy-two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016;40:1755-1765.
• [3] Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: A case series. J Med Case Rep. 2011;5:296.
• [4] Fodor P, Paulseth SPT. Adipose Derived Stromal Cell (ADSC) injections for pain management of osteoarthritis in the human knee joint. Aesthetic Surgery Journal. 2016;36:229-236.
• [5] Koga H, et al. Mesenchymal stem cell-based therapy for cartilage repair: A review. Knee Surg Sports Traumatol Arthrosc. 2009;17:1289-1297.
• [6] Harman R, et al. A prospective, randomized, masked and placebo-controlled efficacy study of intra-articular of allogeneic adipose stem cells for treatment of osteoarthritis in dogs. Front Vet Sci. 2016;3:81.
• [7] Augello A, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56:1175-1186.
• [8] Gonzalez-Rey E, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-248.
• [9] Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther. 2008;10:223.
• [10] Zheng ZH, et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology. 2008;47:22-30.
• [11] Ryan JM, et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.
• [12] Ryan AE, et al. Chondrogenic differentiation increases anti-inflammatory properties of mesenchymal stem cells. Mol Ther. 2014;22:655-667.
• [13] Holmqvist AS, et al. Assessment of late mortality risk after allogeneic blood or marrow transplantation performed in childhood. JAMA Oncology. 2018;4:e182453.
• [14] Sanz J, et al. Bloodstream infections in adult patients undergoing cord blood transplantation from unrelated donors after myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2015;21:755-760.
• [15] Parody R, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: Comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:734-748.
• [16] Yazaki M, et al. Incidence and risk factors of early bacterial infections after unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2009;15:439-446.
• [17] Narimatsu H, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant. 2005;11:429-436.
• [18] Tomonari A, et al. Bacterial bloodstream infection in neutropenic adult patients after myeloablative cord blood transplantation: Experience of a single institution in Japan. Int J Hematol. 2007;85:238-241.
• [19] Kilinc MO, et al. The Ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem cell therapy. Clin Transl Med. 2018;7:5.
• [20] Berman, Lander. A prospective safety study of autologous adipose stromal vascular fraction using a specialized surgical processing system. American J Cosm Surg. 2017;1-14.
• [21] Yoshimura K, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208:64-76.
• Berman et al. Prospective Study of Autologous Adipose Derived Stromal Vascular Fraction Containing Stem Cells for the Treatment of Knee Osteoarthritis. Int J Stem Cell Res Ther. 2019;6:064. [DOI: 10.23937/2469-570X/1410064]